T cell antigen receptor vaccines for active therapy of T cell malignancies.
T cell lymphoproliferative disorders continue to be serious management problems, and so alternative therapeutic modalities are continuously being explored. One such strategy involves immunotherapy using the T cell receptor (TCR) as a target. Specifically we are attempting to develop a T cell receptor idiotype (TCR-Id) vaccine because the TCR-Id can serve as a tumor-specific antigen. In this article we will briefly review the rationale for TCR-Id vaccines, the preclinical models as developed in our laboratory, and a discussion of our current plans for a vaccine trial in mycosis fungoides.
Reddy
S A
SA
Stanford University Medical Center, California 94305, USA.
Okada
C
C
Wong
C
C
Bahler
D
D
Levy
R
R
D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D000951:Antigens, Neoplasm / Q000235:genetics / Q000627:therapeutic use; D001483:Base Sequence; D019496:Cancer Vaccines; D005822:Genetic Vectors; D006801:Humans; D007130:Immunoglobulin Idiotypes / Q000627:therapeutic use; D008232:Lymphoproliferative Disorders / Q000628:therapy; D051379:Mice; D009182:Mycosis Fungoides / Q000628:therapy*; D016133:Polymerase Chain Reaction; D011948:Receptors, Antigen, T-Cell / Q000235:genetics / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000628:therapy*; D015996:Survival Rate; D019444:Vaccines, DNA
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D007130:Immunoglobulin Idiotypes; D011948:Receptors, Antigen, T-Cell; D019444:Vaccines, DNA